Online inquiry

IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13116MR)

This product GTTS-WQ13116MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13116MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1043MR IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-621
GTTS-WQ13812MR IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-10987
GTTS-WQ9375MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ12734MR IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-313M32
GTTS-WQ12572MR IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA NV-02
GTTS-WQ9861MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA K7153A
GTTS-WQ10590MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY-3127804
GTTS-WQ657MR IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 8c10
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW